A detailed history of Deutsche Bank Ag\ transactions in Xencor Inc stock. As of the latest transaction made, Deutsche Bank Ag\ holds 37,913 shares of XNCR stock, worth $948,204. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,913
Previous 29,753 27.43%
Holding current value
$948,204
Previous $563,000 35.35%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$15.7 - $21.65 $128,112 - $176,664
8,160 Added 27.43%
37,913 $762,000
Q2 2024

Aug 14, 2024

SELL
$18.21 - $24.5 $22,507 - $30,282
-1,236 Reduced 3.99%
29,753 $563,000
Q1 2024

May 15, 2024

SELL
$18.65 - $26.52 $28,161 - $40,045
-1,510 Reduced 4.65%
30,989 $685,000
Q4 2023

Feb 14, 2024

SELL
$16.53 - $21.42 $9,901 - $12,830
-599 Reduced 1.81%
32,499 $689,000
Q3 2023

Nov 09, 2023

BUY
$20.08 - $25.39 $76,404 - $96,608
3,805 Added 12.99%
33,098 $666,000
Q2 2023

Aug 14, 2023

SELL
$24.77 - $29.9 $272,965 - $329,498
-11,020 Reduced 27.34%
29,293 $731,000
Q1 2023

May 15, 2023

BUY
$25.95 - $36.95 $176,148 - $250,816
6,788 Added 20.25%
40,313 $1.12 Million
Q4 2022

Feb 13, 2023

BUY
$24.79 - $30.86 $209,624 - $260,952
8,456 Added 33.73%
33,525 $872,000
Q3 2022

Nov 14, 2022

SELL
$24.62 - $32.44 $159,783 - $210,535
-6,490 Reduced 20.56%
25,069 $651,000
Q2 2022

Aug 11, 2022

SELL
$19.74 - $29.01 $94,278 - $138,551
-4,776 Reduced 13.14%
31,559 $863,000
Q1 2022

May 13, 2022

SELL
$26.68 - $41.63 $93,646 - $146,121
-3,510 Reduced 8.81%
36,335 $970,000
Q4 2021

Feb 11, 2022

BUY
$33.67 - $43.44 $39,023 - $50,346
1,159 Added 3.0%
39,845 $1.6 Million
Q3 2021

Nov 04, 2021

SELL
$30.65 - $35.68 $31,661 - $36,857
-1,033 Reduced 2.6%
38,686 $1.26 Million
Q2 2021

Aug 11, 2021

SELL
$34.33 - $44.68 $48,096 - $62,596
-1,401 Reduced 3.41%
39,719 $1.37 Million
Q1 2021

May 13, 2021

SELL
$40.81 - $53.88 $126,633 - $167,189
-3,103 Reduced 7.02%
41,120 $1.77 Million
Q4 2020

Feb 16, 2021

BUY
$36.63 - $47.63 $359,047 - $466,869
9,802 Added 28.48%
44,223 $1.93 Million
Q3 2020

Nov 12, 2020

BUY
$30.09 - $43.02 $68,514 - $97,956
2,277 Added 7.08%
34,421 $1.34 Million
Q2 2020

Aug 13, 2020

SELL
$27.76 - $33.42 $647,613 - $779,655
-23,329 Reduced 42.05%
32,144 $1.04 Million
Q1 2020

May 14, 2020

SELL
$20.69 - $37.79 $494,573 - $903,332
-23,904 Reduced 30.11%
55,473 $1.66 Million
Q4 2019

Feb 14, 2020

BUY
$32.75 - $41.43 $2.15 Million - $2.72 Million
65,540 Added 473.66%
79,377 $2.73 Million
Q3 2019

Nov 14, 2019

SELL
$33.73 - $46.27 $442,301 - $606,738
-13,113 Reduced 48.66%
13,837 $466,000
Q2 2019

Aug 14, 2019

SELL
$29.6 - $40.93 $689,058 - $952,809
-23,279 Reduced 46.35%
26,950 $1.1 Million
Q1 2019

May 15, 2019

BUY
$27.85 - $38.09 $391,431 - $535,354
14,055 Added 38.85%
50,229 $1.56 Million
Q4 2018

Feb 14, 2019

SELL
$32.39 - $42.05 $3.32 Million - $4.31 Million
-102,566 Reduced 73.93%
36,174 $1.31 Million
Q3 2018

Dec 21, 2021

BUY
$35.69 - $47.65 $1.64 Million - $2.19 Million
45,927 Added 49.48%
138,740 $5.41 Million
Q3 2018

Nov 14, 2018

SELL
$35.69 - $47.65 $488,703 - $652,471
-13,693 Reduced 12.86%
92,813 $3.62 Million
Q2 2018

Apr 21, 2020

BUY
$28.41 - $42.41 $693,232 - $1.03 Million
24,401 Added 29.72%
106,506 $3.94 Million
Q2 2018

Aug 14, 2018

BUY
$28.41 - $42.41 $884,232 - $1.32 Million
31,124 Added 61.05%
82,105 $3.04 Million
Q1 2018

Oct 18, 2019

BUY
$21.18 - $33.78 $205,128 - $327,159
9,685 Added 23.45%
50,981 $1.53 Million
Q1 2018

May 15, 2018

SELL
$21.18 - $33.78 $2.42 Million - $3.85 Million
-114,047 Reduced 73.42%
41,296 $1.24 Million
Q4 2017

Feb 14, 2018

BUY
$19.29 - $24.83 $1.29 Million - $1.66 Million
66,656 Added 75.16%
155,343 $3.4 Million
Q3 2017

Nov 14, 2017

BUY
$19.61 - $23.35 $1.74 Million - $2.07 Million
88,687
88,687 $2.03 Million

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.49B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.